Investigational drug · Phase 3
PPV23
Also called: 23-valent Pneumococcal Polysaccharide Vaccine, lot 1, lot 2, lot 3, referred to as PPV23, 23-PPV
Not approved by FDA. In 6 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Healthy Volunteers, Streptococcus Pneumoniae Infection, Pneumococcal Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
6
4 still active
All registered trials
48
Any phase or sponsor naming "PPV23"
First trial start
2018
Dec 28, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PPV23", any sponsor or status.
Conditions studied
As listed on its trial records.
- Healthy Volunteers
- Streptococcus Pneumoniae Infection
- Pneumococcal Disease
- Relapsing Multiple Sclerosis
- Pneumococcal Vaccines
- Diphtheria
- Tetanus
- Pertussis
Approved drugs for the same conditions: Multiple sclerosis · Pneumonia · Neurology · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "PPV23" as an intervention, largest first.
- A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide VaccinePivotal-lookingCompleted
Sinovac Biotech Co., LtdIndustry
NCT05499351 · 3,000 participants · Start Oct 15, 2021 · Primary completion Dec 5, 2021
Drug: Adult group in immunogenicity and safety study of combined immunization; Elderly group in immunogenicity and safety study of combined immunization and 2 more · For: COVID-19
Sites: Beijing, China
- Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23Pivotal-lookingStatus unknown
Centers for Disease Control and Prevention, ChinaGovernment (non-federal)
NCT05298800 · 3,000 participants (planned) · Start Oct 8, 2021 · Primary completion Dec 31, 2022
Drug: Vaccine · For: Safety; Immunogenicity, Vaccine; COVID-19 Vaccines and 2 more
Sites: Beijing, China · 3 sites in all
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)Pivotal-lookingCompleted
CanSino Biologics Inc.Industry
NCT06708286 · 1,820 participants · Start Dec 20, 2024 · Primary completion Jul 1, 2025
Drug: Tetanus, Reduced Diphtheria and Acellular Pertussis (Five Components) Combined Vaccine, Adsorbed (Tdcp)); 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) and 8 more · For: Diphtheria; Tetanus; Pertussis
Sites: Kaihua, China
- Safety and Immunogenicity of a Newly 23-valent Pneumococcal Polysaccharide Vaccine in Chinese Adults and ChildrenPivotal-lookingCompleted
Walvax Biotechnology Co., Ltd.Industry
NCT02285036 · 1,660 participants · Start Sep 2012 · Primary completion Dec 2012
Drug: vaccination PPV23; vaccination PNEUMOVAX 23 · For: Pneumococcal Infectious Diseases
Sites: Nanning, China
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)Pivotal-lookingCompleted
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT03547167 · 1,515 participants · Start Jul 16, 2018 · Primary completion Jan 20, 2020
Drug: V114; Prevnar 13™ and 1 more · For: Pneumococcal Infections
Sites: Chinle, Arizona; Fort Defiance, Arizona; Glendale, Arizona · 78 sites in all
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4Pivotal-lookingStatus unknown
China National Biotec Group Company LimitedIndustry
NCT05079152 · 1,404 participants · Start May 6, 2021 · Primary completion May 29, 2021
Drug: COVAX+PPV23;COVAX+IIV4; COVAX only (1st and 2nd dose) and 1 more · For: Influenza, Human; Pneumonia, Pneumococcal; COVID-19 Pneumonia
Sites: Guangzhou, China; Zhengzhou, China; Wuhan, China
- Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4Pivotal-lookingCompleted
China National Biotec Group Company LimitedIndustry
NCT04559204 · 1,224 participants · Start Sep 11, 2020 · Primary completion Nov 26, 2020
Drug: IIV4 and PPV23; IIV4 and 1 more · For: Influenza, Human; Pneumonia, Pneumococcal
Sites: Quanzhou, China; Qingzhen, China; Hongqiao, China · 4 sites in all
- Immunogenicity and Safety of BBIBP-Corv Coadministered With PPV23 and IIV4 in Hemodialysis PopulationPivotal-lookingStatus unknown
China National Biotec Group Company LimitedIndustry
NCT05480436 · 1,200 participants (planned) · Start Aug 5, 2022 · Primary completion Jan 30, 2023
Drug: coadministration; COVID-19 vaccine and 1 more · For: Hemolysis; COVID-19
Sites: Changsha, China; Chengdu, China; Guiyang, China
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4Pivotal-lookingCompleted
China National Biotec Group Company LimitedIndustry
NCT04790851 · 1,133 participants · Start Mar 10, 2021 · Primary completion Sep 5, 2021
Drug: COVAX+IIV4; COVAX+PPV23; COVAX only (1st and 2nd dose) and 1 more · For: Influenza, Human; Pneumonia, Pneumococcal; Covid19
Sites: Chengdu, China; Shanghai, China; Taiyuan, China
- Phase Ⅱ Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate VaccinePivotal-lookingCompleted
Jiangsu Province Centers for Disease Control and PreventionResearch network
NCT07035054 · 992 participants · Start Apr 20, 2024 · Primary completion Nov 30, 2024
Drug: low dose-1; low dose-2 and 2 more · For: Streptococcus Pneumoniae Pneumonia
Sites: Nanjing, China
Newest research
PubMed records naming it or its code names, newest first.
- A cross-sectional study of vaccination behavior and willingness regarding respiratory disease-related vaccines among the elderly in Beijing, China.
Zhang J, Liu P, Chu P, et al. · Hum Vaccin Immunother 2026
- Vaccination in patients with cancer: Gaps in coverage, barriers, and the role of clinician recommendations.
Kayaalp M, Akkuş E, Arslan Ç, et al. · Hum Vaccin Immunother 2026
- Safety and immunogenicity of the 24-valent pneumococcal conjugate vaccine in healthy Chinese adults: two single-center, randomized, double-blind Phase 1 and Phase 2 trials.
Wang K, Hu J, Chen H, et al. · Expert Rev Vaccines 2026
- Evaluating a multi-vaccine respiratory immunization strategy involving SARS-CoV-2, pneumococcal, and influenza vaccines in adults: A randomized, open-label, multicenter, controlled, non-inferiority Phase IV trial in China.
Shi X, Han S, Wu C, et al. · Hum Vaccin Immunother 2026
- Projected epidemiological impact of lowering the adult pneumococcal vaccination age from 60 to 50 years in Germany.
Sharomi O, de Lepper M, Lang LM, et al. · Hum Vaccin Immunother 2026
- Cost-effectiveness analysis of 23-valent pneumococcal polysaccharide vaccine for elderly in Zhejiang province, China.
Yu Z, Han S, Hu Y · Hum Vaccin Immunother 2026
Also in development for Healthy Volunteers
- PCV21 vaccinePhase 35 trials
Sanofi · Pneumococcal Immunization, Healthy Volunteers
- TDVTAK-003, Tetravalent Dengue VaccinePhase 35 trials
Takeda · Dengue Fever, Healthy Volunteers
- DTap-HepB-IPV-Hib vaccineHexyon, Infanrix hexaPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunization, Pneumococcal Immunization
- MenACYW conjugate vaccineNimenrixPhase 34 trials
Sanofi · Healthy Volunteers, Meningococcal Immunisation, Meningococcal Immunization
- poliomyelitis vaccinePhase 33 trials
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd · Healthy Volunteers, Whooping Cough, Diphtheria
- HexaximHexaxim Vaccine, DTaP-IPV-Hib-HepB vaccinePhase 32 trials
Sanofi · Pneumococcal Immunization, Meningococcal Immunisation, Healthy Volunteers
- IIV-HDstandalonePhase 32 trials
Sanofi · COVID-19 Immunization, Influenza Immunization, Immunization
- NVXC19EU licensed, standalonePhase 31 trial
Sanofi · Immunization, Healthy Volunteers, COVID-19 Immunization
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.